Provention Bio
United States
186 articles with Provention Bio
-
Sanofi will acquire diabetes leader Provention Bio for $25 per share for a total of $2.9 billion, the companies announced Monday.
-
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
3/13/2023
Provention Bio, Inc. today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.
-
Provention Bio Announces the Grant of Inducement Awards - March 03, 2023
3/3/2023
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 10,000 shares of common stock.
-
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
2/23/2023
Provention Bio, Inc. today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023, before the opening of the U.S. financial markets.
-
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
2/13/2023
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the closing of the $35 million equity investment from Sanofi US under the previously announced Co-Promotion Agreement and Securities Purchase Agreement (the "Purchase Agreement").
-
Provention Bio to Present at the SVB Securities Global Biopharma Conference
2/8/2023
Provention Bio, Inc. today announced that management will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15th, 2023 at 11:20am EST.
-
Provention Bio Announces the Grant of Inducement Awards - February 03, 2023
2/3/2023
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to 8 non-executive employees to purchase an aggregate of 124,000 shares of common stock.
-
Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®
2/2/2023
Provention Bio, Inc. announced the close of the $40 million second tranche under the previously announced term loan facility of up to $125 million with Hercules Capital, Inc., a leader in customized financing for companies in life sciences.
-
Provention Bio Announces the Grant of Inducement Awards - Jan 06, 2023
1/6/2023
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to 58 non-executive employees to purchase an aggregate of 763,000 shares of common stock.
-
Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
1/5/2023
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced the appointment of Rita Jain, M.D., to the Company's Board of Directors.
-
Provention Bio Announces the Grant of Inducement Awards - December 02, 2022
12/2/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to three non-executive employees to purchase an aggregate of 84,000 shares of common stock.
-
The FDA has approved Provention’s BLA for intravenous antibody TZIELD to delay stage 3 type 1 diabetes, making it the first disease-modifying drug indicated to slow disease progression.
-
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
11/17/2022
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company") today announced that the United States Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for TZIELD (teplizumab-mzwv), an anti-CD3-directed antibody, for intravenous use, as the first and only immunomodulatory treatment to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with stage 2 T1D.
-
The FDA is gearing up for deadlines and PDUFA dates in mid-November with Seagen, Provention, Clarus and Tolmar, and Ligand and Travere.
-
Provention Bio Announces the Grant of Inducement Awards - November 04, 2022
11/4/2022
Provention Bio, Inc. announced that the Company granted stock options to five non-executive employees to purchase an aggregate of 80,000 shares of common stock.
-
Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
11/3/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, reported financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022
10/13/2022
Provention Bio, Inc. today announced that it will report its third quarter 2022 financial results on Thursday, November 3, 2022, before the opening of the U.S. financial markets.
-
Provention Bio Announces the Grant of Inducement Awards - October 07, 2022
10/7/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a non-executive employee to purchase an aggregate of 10,000 shares of common stock.
-
Provention Bio entered a co-promotion agreement with Sanofi ahead of the possible November approval of teplizumab. If approved, the drug would be the first approved to modify T1D.
-
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
10/6/2022
Sanofi US to co-promote teplizumab, adding it to its current commercial activities in diabetes care, leveraging its existing best-in-class customer-facing field teams Provention Bio, Inc. retains all rights to teplizumab Commercialization activities are dependent on U.S. FDA approval of teplizumab, potentially on November 17, 2022.